RTA Laboratuvarlari Biyolojik (RTALB) - Total Assets
Based on the latest financial reports, RTA Laboratuvarlari Biyolojik (RTALB) holds total assets worth TL2.23 Billion TRY (≈ $49.90 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore cash flow to debt ratio of RTA Laboratuvarlari Biyolojik to assess how comfortably operating cash covers total debt obligations.
RTA Laboratuvarlari Biyolojik - Total Assets Trend (2010–2024)
This chart illustrates how RTA Laboratuvarlari Biyolojik's total assets have evolved over time, based on quarterly financial data. See RTALB book value for net asset value and shareholders' equity analysis.
RTA Laboratuvarlari Biyolojik - Asset Composition Analysis
Current Asset Composition (December 2024)
RTA Laboratuvarlari Biyolojik's total assets of TL2.23 Billion consist of 8.1% current assets and 91.9% non-current assets.
| Asset Category | Amount (TRY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | TL0.00 | 0.3% |
| Accounts Receivable | TL60.30 Million | 3.1% |
| Inventory | TL40.86 Million | 2.1% |
| Property, Plant & Equipment | TL0.00 | 0.0% |
| Intangible Assets | TL131.16K | 0.0% |
| Goodwill | TL0.00 | 0.0% |
Asset Composition Trend (2010–2024)
This chart illustrates how RTA Laboratuvarlari Biyolojik's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see RTA Laboratuvarlari Biyolojik market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: RTA Laboratuvarlari Biyolojik's current assets represent 8.1% of total assets in 2024, an increase from 0.0% in 2010.
- Cash Position: Cash and equivalents constituted 0.3% of total assets in 2024, down from 32.5% in 2010.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 2.0% in 2010.
- Asset Diversification: The largest asset category is accounts receivable at 3.1% of total assets.
RTA Laboratuvarlari Biyolojik Competitors by Total Assets
Key competitors of RTA Laboratuvarlari Biyolojik based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $8.68 Billion |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥8.59 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Tango Therapeutics Inc
NASDAQ:TNGX
|
USA | $398.69 Million |
|
TELIX Pharmaceuticals Ltd
AU:TLX
|
Australia | AU$1.19 Billion |
|
Inner Mongolia Furui Med Sci
SHE:300049
|
China | CN¥3.42 Billion |
|
Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAX
|
USA | $553.60 Million |
|
Damora Therapeutics, Inc.
NASDAQ:DMRA
|
USA | $260.53 Million |
RTA Laboratuvarlari Biyolojik - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.24 | 1.60 | 1.99 |
| Quick Ratio | 1.84 | 1.18 | 1.18 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | TL95.63 Million | TL77.71 Million | TL59.76 Million |
RTA Laboratuvarlari Biyolojik - Advanced Valuation Insights
This section examines the relationship between RTA Laboratuvarlari Biyolojik's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.83 |
| Latest Market Cap to Assets Ratio | 0.02 |
| Asset Growth Rate (YoY) | 6.5% |
| Total Assets | TL1.92 Billion |
| Market Capitalization | $33.37 Million USD |
Valuation Analysis
Below Book Valuation: The market values RTA Laboratuvarlari Biyolojik's assets below their book value (0.02x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: RTA Laboratuvarlari Biyolojik's assets grew by 6.5% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for RTA Laboratuvarlari Biyolojik (2010–2024)
The table below shows the annual total assets of RTA Laboratuvarlari Biyolojik from 2010 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | TL1.92 Billion ≈ $43.03 Million |
+6.46% |
| 2023-12-31 | TL1.80 Billion ≈ $40.42 Million |
+143.79% |
| 2022-12-31 | TL740.21 Million ≈ $16.58 Million |
+34.00% |
| 2021-12-31 | TL552.40 Million ≈ $12.37 Million |
+115.34% |
| 2020-12-31 | TL256.52 Million ≈ $5.75 Million |
+161.33% |
| 2019-12-31 | TL98.16 Million ≈ $2.20 Million |
+48.61% |
| 2018-12-31 | TL66.05 Million ≈ $1.48 Million |
+4.69% |
| 2017-12-31 | TL63.09 Million ≈ $1.41 Million |
+3.61% |
| 2016-12-31 | TL60.89 Million ≈ $1.36 Million |
-1.17% |
| 2015-12-31 | TL61.61 Million ≈ $1.38 Million |
+25.63% |
| 2014-12-31 | TL49.04 Million ≈ $1.10 Million |
+67.08% |
| 2013-12-31 | TL29.35 Million ≈ $657.41K |
+43.53% |
| 2012-12-31 | TL20.45 Million ≈ $458.03K |
+23.16% |
| 2011-12-31 | TL16.60 Million ≈ $371.89K |
-1.50% |
| 2010-12-31 | TL16.86 Million ≈ $377.55K |
-- |
About RTA Laboratuvarlari Biyolojik
RTA Laboratuvarlari Biyolojik Urunler Ilac ve Makine Sanayi Ticaret A.S. engages in the research, development, and production of microbiology and molecular biology products in Turkey. It offers microbiology products, including petri dish, tube and bottle, chromogenic media, blood culture bottle, tuberculosis diagnostic, rapid test, microbiological stain, hygislide, surcheck media, membrane, paint… Read more